


Claims

1. A compound represented by formula (I):



wherein

Ring A represents a benzene ring-an optionally substituted C₆₋₁₄ aromatic hydrocarbon ring;

R¹ represents a hydrogen atom or an optionally substituted C₁₋₆ alkyl group;

R² and R³ each independently represent an optionally substituted a C₁₋₆ alkyl group;

R⁴ represents a C₆₋₁₄ aryl group, a 5- or 6-membered monocyclic aromatic heterocyclic group, or a C₁₋₆ alkyl group, each of which is optionally substituted with one or two substituents selected from the group consisting of

(a) a halogen atom,

(b) a C₁₋₆ alkyl group which is optionally substituted with one to three halogen atoms, and

(c) a C₁₋₆ alkoxy group which is optionally substituted with one to three halogen atoms-an optionally

~~substituted C₆₋₁₄ aryl group, an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group or an optionally substituted C₁₋₆ alkyl group; and~~

R⁵ and R⁶ each independently represent a hydrogen atom or a ~~halogen~~ fluorine atom, or a salt thereof.

~~2. The compound or a salt thereof according to claim 1, wherein Ring A is a benzene ring.~~

~~3. The compound or a salt thereof according to claim 1, wherein R¹ is a hydrogen atom.~~

~~4. The compound or a salt thereof according to claim 1, wherein each of R² and R³ is a C₁₋₆ alkyl group.~~

~~5. The compound or a salt thereof according to claim 1, wherein~~

~~R⁴ is a C₆₋₁₄ aryl group, a 5- or 6-membered monocyclic aromatic heterocyclic group, or a C₁₋₆ alkyl group, each of which is optionally substituted with one or two substituents selected from the group consisting of~~

~~(a) a halogen atom,~~

~~(b) a C₁₋₆ alkyl group which is optionally substituted with one to three halogen atoms, and~~

~~(c) a C₁₋₆ alkoxy group which is optionally substituted with one to three halogen atoms.~~

~~6. The compound or a salt thereof according to claim 1, wherein R⁵ and R⁶ each independently represent a hydrogen atom or a fluorine atom.~~

~~7. The compound or a salt thereof according to claim 1, wherein~~

~~Ring A is a benzene ring;~~

~~R¹ is a hydrogen atom;~~

~~each of R² and R³ is C₁₋₆ alkyl;~~

~~R⁴ is a C₆₋₁₄ aryl group, a 5- or 6-membered monocyclic aromatic heterocyclic group, or a C₁₋₆ alkyl group, each of which is optionally substituted with one or two substituents selected from the group consisting of~~

~~(a) a halogen atom,~~

~~(b) a C₁₋₆ alkyl group which is optionally substituted with one to three halogen atoms, and~~

~~(c) a C₁₋₆ alkoxy group which is optionally substituted with one to three halogen atoms; and~~

~~R⁵ and R⁶ each independently represent a hydrogen atom or a fluorine atom.~~

82. The compound or a salt thereof according to claim 1, wherein

Ring A is a benzene ring;

R¹ is a hydrogen atom;

each of R² and R³ is C₁₋₆ alkyl;

R⁴ is a phenyl group which is substituted with one or two substituents selected from the group consisting of

(a) a halogen atom, and

(b) a C₁₋₆ alkyl group which is optionally substituted with one to three halogen atoms; and
each of R⁵ and R⁶ is a hydrogen atom.

~~93~~. ((1S,5R)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl)((5R)-7,7-dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)methanone or a salt thereof.

~~104~~. (1-(3,5-Dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl)((5R)-7,7-dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)methanone or a salt thereof.

~~115~~. (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hex-3-yl)((5R)-7,7-dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)methanone or a salt thereof.

~~126~~. A medicament comprising the compound or a salt thereof according to any one of claims 1 to ~~115~~.

~~137~~. The medicament according to claim ~~126~~, wherein the medicament is a calcium-sensing receptor antagonist.

~~148~~. The medicament according to claim ~~126~~, wherein the medicament is an agent for preventing or treating heart

failure.

~~159~~. The medicament according to claim ~~126~~, wherein the medicament is an agent for preventing or treating pulmonary hypertension.

~~1610~~. Use of the compound or a salt thereof according to any one of claims 1 to ~~115~~, in the manufacture of a medicament for preventing or treating heart failure.

~~1711~~. Use of the compound or a salt thereof according to any one of claims 1 to ~~115~~, in the manufacture of a medicament for preventing or treating pulmonary hypertension.

~~1812~~. The compound or a salt thereof according to any one of claims 1 to ~~115~~, for use in medicine.

~~1913~~. The compound or a salt thereof for use according to claim ~~1812~~, wherein the medicine is for use in preventing or treating a disease ~~with which the calcium-sensing receptor is associated~~ selected from the group consisting of heart failure, pulmonary hypertension, hyperthyroidism, hypocalcemia, osteoarthropathy and central nervous system diseases.

~~2014~~. The compound or a salt thereof for use according to claim ~~1813~~, wherein the ~~medicine is for use in~~

~~preventing or treating~~ disease is heart failure.

~~2115~~. The compound or a salt thereof for use according to claim ~~1813~~, wherein ~~the medicine is for use in~~ ~~preventing or treating~~ the disease is pulmonary hypertension.